Eli Lilly and Company's LLY stock has declined around 7.2% in the past month after gaining sharply earlier in 2026 and trading near record levels. At around 26.3x forward earnings, LLY continues to command a premium valuation, making the stock more vulnerable to profit-taking and broader market volatility. Investors have also become more focused on competition in the fast-growing obesity-drug market, particularly in the oral GLP-1 segment, where Lilly's oral GLP-1 pill Foundayo is competing with Novo Nordisk's NVO Wegovy pill. Nevertheless, continued strength in Mounjaro, Zepbound and Foundayo, along with Lilly's broader pipeline, supports the company's long-term growth prospects.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.